17/05/2023 – AB Science today summarizes the key messages delivered to an audience of key opinion leaders and decision-makers in the field of ALS research and healthcare policy, during an Panel Discussion at the ALS Drug Development Summit in Boston, USA (May 16-18, 2023)
09/05/2023 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
28/04/2023 – AB Science reports its revenues for the year 2022 and provides an update on its activities
27/04/2023 – AB Science today summarizes the presentation that was made on masitinib in amyotrophic lateral sclerosis at the American Academy of Neurology (AAN) 2023 Annual Meeting in Boston, USA
27/04/2023 – Presentation on masitinib in amyotrophic lateral sclerosis delivered at the American Academy of Neurology 2023 Annual Meeting
24/04/2023 – AB Science announces today the success of its capital increase via a private placement for a final amount of 15.0 million euros
21/04/2023 – AB Science announces today the implementation of a new strategy and the launch, in support of this new strategy, of a capital increase
18/04/2023 – AB Science today announced that the patent office of Japan has issued a Notice of Allowance (NOA) for a patent relating to methods of treating amyotrophic lateral sclerosis (ALS) with its lead compound masitinib
12/04/2023 – AB Science today announced that Professor Albert Ludolph, MD, PhD (Chairman of the Department of Neurology at the University Hospital and Medical Faculty of Ulm), will deliver a presentation on masitinib in amyotrophic lateral sclerosis (ALS) to an audience of key opinion leaders in the field of ALS healthcare, at the up-coming American Academy…
04/04/2023 – AB Science today provides an update on the schedule for the evaluation by the European Medicines Agency (EMA) and by Health Canada of its applications for conditional approval of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
16/03/2023 – Presentation of the AB Science Microtubule Destabilizer Agents platform webcast
15/03/2023 – AB Science will host a live webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/2 with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform
13/03/2023 – AB Science today announces a case report from the initial stage of its Phase I/II study (AB18001) evaluating AB8939, a microtubule destabilizer, in patients with refractory and relapsed acute myeloid leukemia (AML)
28/02/2023 – AB Science today announced publication of results from its positive pivotal phase 3 trial of masitinib in mild-to-moderate Alzheimer’s disease (AD) in Alzheimer’s Research & Therapy
31/01/2023 – AB Science announced today that it has received payment of €6.0 million as the second tranche of a €15 million loan from the European Investment Bank (EIB)
29/12/2022 – AB Science announced today that its Phase III clinical trial (AB20009) in progressive forms of multiple sclerosis has been approved by the US Food and Drug Administration (FDA)
27/12/2022 – AB Science today announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS)
22/12/2022 – AB Science announced today that it has received payment of €6.0 million as the first tranche of a €15 million loan from the European Investment Bank (EIB)
13/12/2022 – AB Science announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis
21/11/2022 – AB Science today announced that it has received an Investigational New Drug (IND) approval letter from the FDA to initiate Phase III study (AB21004) in patients with mild to moderate Alzheimer’s disease
10/10/2022 – AB Science today announces that the first authorizations have been received to initiate its phase 3 confirmatory study (AB21004) evaluating masitinib in patients with mild to moderate Alzheimer’s Disease
30/09/2022 – AB Science today reports its revenues for the first half of 2022 and provides an update on its activities
14/09/2022 – AB Science announced continuation of the Phase 2 study evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
24/08/2022 – AB Science today announced that it has filed an application for conditional Marketing Authorization to the European Medicines Agency (EMA) for Alsitek (masitinib) in the treatment of amyotrophic lateral sclerosis (ALS)
07/06/2022 – AB Science today announced the publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids (OCS) in the peer-reviewed Journal of Asthma and Allergy
26/05/2022 – AB Science today announces that Health Canada has issued a screening acceptance letter for the application of masitinib in the treatment of amyotrophic lateral sclerosis (ALS)
29/04/2022 – AB Science reports its revenues for the year 2021 and provides an update on its activities
28/04/2022 – AB Science announced the continuation of the Phase 2 study evaluating masitinib in combination with isoquercetin in COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB)
29/03/2022 – AB Science acknowledges the decision of the Enforcement Committee of the French market regulator (AMF), which has cleared its Chief Executive Officer, Alain Moussy, in a decision concerning possible insider trading.
28/02/2022 – Presentation of the webcast held on February 28, 2022 on masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indications
28/02/2022 – AB Science announces today that it reached an agreement with a historical investor on a financing of USD 8.5 million through the issuance of bonds convertible into new ordinary shares with attached warrants
24/02/2022 – AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment of amyotrophic lateral sclerosis (ALS) in Canada under the NOC/c procedure and to provide an update on its clinical program in all indications
22/02/2022 – AB Science announced the publication of results from its positive pivotal phase 3 trial of masitinib in progressive forms of multiple sclerosis in the peer-reviewed journal Neurology® Neuroimmunology & Neuroinflammation
21/02/2022 – AB Science today announces that Health Canada has granted authorization to file a New Drug Submission for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) under the Notice of Compliance with Conditions (NOC/c) policy
12/02/2022 – AB Science wishes to provide clarifications following press articles published after the public hearing of the Enforcement Committee of the French market regulator (AMF) on Friday, February 11, 2022
07/02/2022 – AB Science will deliver a presentation on the Amyotrophic Lateral Sclerosis (ALS) masitinib development program at the 2022 ALS Drug Development Summit
02/02/2022 – AB Science today announces that it has been authorized by the Swedish Medical Products Agency, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS)
19/01/2022 – AB Science today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase II study (AB20006) in patients with severe mast cell activation syndrome
03/01/2022 – AB Science today announces that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase III study (AB20009) evaluating masitinib in patients with Primary Progressive Multiple Sclerosis (PPMS) or non-active Secondary Progressive Multiple Sclerosis (nSPMS)
29/11/2021 – AB Science today announced that the first patient has been dosed in the phase 2 trial evaluating the antiviral activity of masitinib in patients who have a confirmed diagnosis of COVID-19
22/11/2021 – AB Science today announces that its Phase I/II study (AB18001) evaluating AB8939 in patients with refractory and relapsed AML and refractory myelodysplastic syndrome (MDS) has received Investigational New Drug (IND) approval by the U.S. Food and Drug Administration (FDA)
18/11/2021 – AB Science today announced that it has received authorization from the United States Food and Drug Administration (FDA) to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with amyotrophic lateral sclerosis (ALS)
18/10/2021 – AB Science announced that it has been authorized by the French Medicine Agency, ANSM, to initiate a Phase I/II study (AB18001) evaluating AB8939 in patients with refractory and relapsed AML
04/10/2021 – AB Science today announced that its clinical development program of masitinib in adult patients with mast cell activation syndrome (MCAS) has been approved by the U.S. Food and Drug Administration (FDA)
30/09/2021 – AB Science today reports its revenues for the first half of 2021 and provides an update on its activities
28/09/2021 – AB Science today announced that a new clinical trial with masitinib in patients with symptomatic mild and moderate COVID-19 has been approved by the Regulatory Authorities of Russia and South Africa
22/09/2021 – AB Science today announced that its clinical trial with AB8939 in adult patients with relapsed/refractory acute myeloid leukemia (AML) has been approved by Health Canada
20/09/2021 – AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
16/09/2021 – AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)
14/09/2021 – AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
13/09/2021 – AB Science today announced that results from masitinib study AB12003 in metastatic castrate refractory prostate cancer, have been presented as a podium presentation at the 2021 American Urological Association
02/09/2021 – AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
25/08/2021 – AB Science announced today that it has received authorization from the French National Agency (ANSM) to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB15003) in mastocytosis
23/08/2021 – AB Science today announced that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in amyotrophic lateral sclerosis (ALS)
19/08/2021 – AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib
06/08/2021 – AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders
29/07/2021 – AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC)
22/07/2021 – AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)
20/07/2021 – AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern
19/07/2021 – AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo
12/07/2021 – AB Science announces the validation of its Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France
01/07/2021 – AB Science announces today the results of the Combined General Shareholders’ Meeting of June 30, 2021
28/06/2021 – AB Science announced today that it has signed an agreement with historical shareholders to implement a joint strategy to increase the value of masitinib
10/06/2021 – AB Science today announced that results from masitinib study AB12005 in pancreatic cancer have been presented at the 2021 ASCO Annual Meeting
08/06/2021 – AB Science is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib
08/06/2021 : Presentation of the webcast that was held following the voluntary hold of clinical studies with masitinib
02/06/2021 – AB Science will host a live webcast on June 3, 2021 to provide details on the decision to suspend voluntarily the clinical studies with masitinib
01/06/2021 – AB Science announced today that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide
26/05/2021 – AB Science communicated the results from Phase 3 study evaluating masitinib in prostate cancer during the webcast that was held on May 25, 2021
25/05/2021 – Presentation of the webcast held on May 25, 2021 on masitinib in prostate Cancer Download PDF
21/05/2021 – AB Science will host a live webcast on May 25, 2021 to discuss recently reported results from the Phase 2B/3 masitinib trial in prostate cancer
20/05/2021 – AB Science today announced that results from masitinib study AB12005 in pancreatic cancer, have been selected for presentation at the upcoming ASCO Annual Meeting
30/04/2021 – AB Science reports its annual financial results as of 31 December, 2020
29/04/2021 – AB Science today announces that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint
14/04/2021 – AB Science today announces that it has received financing approval from Société Générale, Bpifrance and Banque Populaire for a total of EUR 6 million in the form of state-guaranteed loans
06/04/2021 – AB Science announces the signing of an exclusive licensing agreement with the University of Chicago to conduct research for the prevention and treatment of Covid-19
31/03/2021 – AB Science provides an update on the expected timelines for the read-out of its masitinib Phase 3 study (AB12003) in metastatic castrate-resistant prostate cancer
08/03/2021 – AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in neurodegenerative disorders including Alzheimer’s Disease
23/02/2021 – AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer
25/01/2021 – AB Science announces that a new independent publication confirms that masitinib has anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19
23/12/2020 – Read the interview of Alain Moussy, CEO of AB Science, in Boursorama
21/12/2020 – AB Science announces today the success of its capital raise for a total amount of 15 million euros
18/12/2020 – AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
17/12/2020 – Presentation of the webcast held on December 17, 2020 on masitinib in Alzheimer’s Disease
17/12/2020 – AB Science provides the results of the Extraordinary Shareholders’ Meeting of December 16, 2020
17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
16/12/2020 – AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
16/12/2020 – AB Science announces that Phase 2B/3 study evaluating masitinib in Alzheimer’s disease met its primary endpoint
08/12/2020 – AB Science will host a live webcast on December 11, 2020 with key opinion leaders to discuss recently reported results from the Phase 3 masitinib trial in pancreatic cancer
04/12/2020 – AB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain met its primary objective to demonstrate increase in survival
30/11/2020 – AB Science announces the signature of a 15.0 million financing deal with the European Investment Bank to support clinical development of masitinib in Covid-19
16/11/2020 – AB Science secures equity financing for a maximum of 4 million shares with Alpha Blue Ocean’s PACT
29/10/2020 – AB Science announces a financing of 4.5 million euros through the issuance of bonds convertible into new ordinary shares
20/10/2020 – AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
13/10/2020 – Results from masitinib study AB07015 in severe asthma selected for presentation at an American Thoracic Society (ATS) symposium held on October 16, 2020
30/09/2020 – AB Science reports its revenues for the first half of 2020
14/09/2020 – AB Science presents Phase 2B/3 study results in Progressive Multiple Sclerosis at the world’s largest Multiple Sclerosis research conference
08/09/2020 – AB Science to present results from its Phase 3 AB07015 study in severe asthma at the annual European Respiratory Society International Congres
07/09/2020 – AB Science to present results from its Phase 2B/3 AB07002 study in progressive forms of multiple sclerosis at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting
02/09/2020 – New independent research reveals that masitinib has direct anti-viral activity against the SARS-CoV-2 virus in-vitro and is a promising candidate for treating COVID-19
01/09/2020 – AB Science announces the results of the Combined Shareholders’ Meeting of August 31, 2020
08/07/2020 – AB Science announces that new results published in the peer-reviewed Journal of Alzheimer’s Disease support masitinib’s potential mode of action in Alzheimer’s Disease
10/06/2020 – AB Science will present results from AB8939 preclinical program in acute myeloid leukemia at the EHA 2020 Annual Congress
22/05/2020 – AB Science announces the postponement of its annual general shareholders’ meeting
07/05/2020 – AB Science will host a live webcast on masitinib in combination with isoquercetin for the treatment of COVID-19 on Monday May 11, 2020
07/05/2020 – AB Science will present results from its Phase 3 study in severe asthma at the EEACI 2020 Annual Congress
06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
30/04/2020 – AB Science reports its annual financial results as of 31 December, 2019
03/04/2020 – A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies
31/03/2020 – AB Science today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the Company to initiate its masitinib Phase 3 study (AB19001) in amyotrophic lateral sclerosis
09/03/2020 – AB Science provides a summary of the live webcast held on March 6 2020 with key opinion leaders on progressive froms of multiple sclerosis
02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million
20/02/2020 – AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosis
08/01/2020 – FDA green-lights U.S. patient enrollment in masitinib phase 3 study following IND clearance in metastatic castrate-resistant prostate cancer eligible to chemotherapy
23/12/2019 – AB Science announces publication of new results in the peer-reviewed journal Glia that further support masitinib’s potential mode of action in ALS
09/12/2019 – AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
27/11/2019 – AB Science will host a live webcast on masitinib in severe asthma on Monday December 2, 2019
25/11/2019 – AB Science provides a summary of the live webcast on November 20 with key opinion leaders on Indolent Systemic Mastocytosis (ISM)
22/11/2019 – AB Science provides clarification regarding the article in the newspaper Les Echos related to the investigation by the French market authorities
07/11/2019 – AB Science announces positive top-line phase 3 results for oral masitinib in severe asthma
07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA
06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program
06/11/2019 – AB Science has signed a financing agreement in order to pre-finance the 2019 research tax credit
04/11/2019 – AB Science will host a live webcast on indolent systemic mastocytosis on November 20,2019
24/10/2019 – AB Science granted authorization to initiate phase 3 confirmatory study of masitinib in indolent systemic mastocytosis
10/10/2019 – AB Science provides update on masitinib programs timelines
30/09/2019 – AB Science reports its revenues for the first half of 2019
19/08/2019 – AB Science announces the success of a private placement
12/08/2019 – AB science will present a corporate overview at two upcoming healthcare conferences in September 2019, in New York.
05/08/2019 – AB Science provides an update on its masitinib clinical program.
02/08/2019 – AB Science reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma.
22/07/2019 – AB Science Corporate Presentation – July 2019
09/07/2019 – AB Science is providing a summary of the web conference held on July 8, 2019
08/07/2019 – AB Science web conference presentation
08/07/2019 – AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.
04/07/2019 – AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure.
26/06/2019 – AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer’s Disease
14/06/2019 – AB Science web conference presentation
12/06/2019 – AB Science announces the positive recommendation of IDMC following the interim analysis of AB12005 study in the first-line treatment of pancreatic cancer
10/06/2019 – AB Science is providing the upcoming news flow of the Company
10/06/2019 – AB Science is providing an updated coporate overview of the Company
05/06/2019 – AB Science is providing a summary of the web conference held on 5 June, 2019
04/06/2019 – AB Science is providing a summary of the web conference held on 4 June, 2019
04/06/2019 – AB Science web conference presentation (Part 1)
30/05/2019 – AB Science will hold a web conference on its outlook for 2019 on June 4 and 5, 2019 from 5.30 pm to 7pm CET
28/05/2019 – AB Science announces the lifting of the ANSM clinical hold.
30/04/2019 – AB Science reports its annual financial results as of 31 December 2018.
16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.
21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.